Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients by Amalia Azzariti, Simona De Summa, Tommaso M. Marvulli, Ivana De Risi, Giuseppe De Palma, Roberta Di Fonte, Rossella Fasano, Simona Serratì, Sabino Strippoli, Letizia Porcelli, Michele Guida

Subjects: Get full text

Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study by Pengfei Cui, Zhefeng Liu, Guoqiang Wang, Junxun Ma, Yuanyu Qian, Fan Zhang, Chun Han, Yaping Long, Ye Li, Xuan Zheng, Danyang Sun, Jing Zhang, Shangli Cai, Shunchang Jiao, Yi Hu

Subjects: “…anti‐PD‐1…”
Get full text

Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment by Eleonora Sosa Cuevas, Eleonora Sosa Cuevas, Stéphane Mouret, Guillaume Vayssière, Guillaume Vayssière, Siham Kerboua, Siham Kerboua, Pauline Girard, Pauline Girard, Jean-Paul Molens, Jean-Paul Molens, Marc Manceau, Julie Charles, Philippe Saas, Philippe Saas, Caroline Aspord, Caroline Aspord

Subjects: Get full text

Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma by Marek Pasek, Eva Sticová, Emanuel Marques, Vojtěch Tretera, Petr Arenberger, Monika Arenbergerová

Subjects: “…melanoma, anti-PD-1, anti-LAG-3, adverse events…”
Get full text

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

Subjects: “…Anti-PD-1/PD-L1…”
Get full text

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer by Yuanyuan Wang, Chenxi Hu, Tianpeng Du, Jiawen Li, Kaiyuan Hui, Xiaodong Jiang

Subjects: “…anti-PD-1…”
Get full text

Extra-cranial radiotherapy in anti-PD-1-treated melanoma patients: A systematic review by Philippe Saiag, Lucien Lahmi, Elisa Funck-Brentano

Subjects: Get full text

Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients by Alain Gelibter, Lucrezia Tuosto, Angela Asquino, Marco Siringo, Arianna Sabatini, Ilaria Grazia Zizzari, Angelica Pace, Fabio Scirocchi, Fabio Scirocchi, Flavio Valentino, Serena Bianchini, Salvatore Caponnetto, Donatella Paoli, Filippo Bellati, Daniele Santini, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano

Subjects: Get full text

Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma by Mi Meng, Bo Yu, Jie Luo, Yuju Bai, Lin Li, Shicheng Chen, Sisi He, Hu Ma

Subjects: Get full text

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors by Michael S. Chang, MD, Jordan T. Said, MD, Elliot H. Akama-Garren, PhD, Nicole Trepanowski, MD, Ai-Tram N. Bui, MD, Anita Giobbie-Hurder, MS, Nicole R. LeBoeuf, MD, MPH, Rebecca I. Hartman, MD, MPH

Subjects: “…anti-PD-1…”
Get full text

Machine learning-based ultrasomics for predicting response to tyrosine kinase inhibitor in combination with anti-PD-1 antibody immunotherapy in hepatocellular carcinoma: a two-cent... by Yiwen Hu, Yiwen Hu, Linlin Zhang, Linlin Zhang, Qinghua Qi, Shanshan Ren, Shanshan Ren, Simeng Wang, Simeng Wang, Lanling Yang, Juan Zhang, Juan Zhang, Yuanyuan Liu, Yuanyuan Liu, Xiaoxiao Li, Xiaoxiao Li, Xiguo Cai, Shaobo Duan, Shaobo Duan, Shaobo Duan, Lianzhong Zhang, Lianzhong Zhang, Lianzhong Zhang, Lianzhong Zhang

Subjects: Get full text

Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas by Sameer Mir, Abhilash Venugopalan, Jingli Zhang, Nishanth Ulhas Nair, Manjistha Sengupta, Manakamana Khanal, Chaido Stathopoulou, Qun Jiang, Raffit Hassan

Subjects: “…anti‐PD1…”
Get full text

Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma by Mi Meng, Bo Yu, Jie Luo, Yuju Bai, Lin Li, Shicheng Chen, Sisi He, Hu Ma

Subjects: Get full text

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 s... by David Dora, Balazs Ligeti, Tamas Kovacs, Peter Revisnyei, Gabriella Galffy, Edit Dulka, Dániel Krizsán, Regina Kalcsevszki, Zsolt Megyesfalvi, Balazs Dome, Glen J. Weiss, Zoltan Lohinai

Subjects: “…Anti-PD1 immunotherapy…”
Get full text

Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab by Efterpi Zafiriou, Emmanouil Karampinis, Vasileios Papadopoulos, Georgia Stefani, Athanasios Kotsakis, George Vassilopoulos

Subjects: Get full text

GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer by Yujing Xuan, Wenyi Yan, Ruimin Wang, Xibin Wang, Yu Guo, Huilin Dun, Ziyan Huan, Lihua Xu, Ruxia Han, Xianlei Sun, Lingling Si, Nicholas R. Lemoine, Nicholas R. Lemoine, Yaohe Wang, Yaohe Wang, Pengju Wang

Subjects: Get full text

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening by Dan Zhao, Ravindra Deshpande, Kerui Wu, Abhishek Tyagi, Sambad Sharma, Shih-Ying Wu, Fei Xing, Stacey O'Neill, Jimmy Ruiz, Feng Lyu, Kounosuke Watabe

Subjects: Get full text

Development of a Mammalian Cell Line for Stable Production of Anti-PD-1 by Erika Csató-Kovács, Pál Salamon, Szilvia Fikó-Lászlo, Krisztina Kovács, Alice Koka, Mónika András-Korodi, Emőke Antal, Emília Brumă, Brigitta Tőrsők, Szilárd Gudor, Ildikó Miklóssy, Kálmán Csongor Orbán, Csilla Albert, Emese Éva Bálint, Beáta Albert

Subjects: Get full text

Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients by Stéphane Dalle, Estelle Verronese, Axelle N’Kodia, Christine Bardin, Céline Rodriguez, Thibault Andrieu, Anais Eberhardt, Gabriel Chemin, Uzma Hasan, Myrtille Le-Bouar, Julie Caramel, Mona Amini-Adle, Nathalie Bendriss-Vermare, Bertrand Dubois, Christophe Caux, Christine Ménétrier-Caux

Subjects: Get full text

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer by Shuailei Dong, Chen Wei, Xueting Wang, Xinyi Yang, Wei Shen, Shuyi Li, Jiye Xu, Yijie Ma, Liangyu Bie, Wenyue Yu, Ning Li

Subjects: Get full text